EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial)

Suhana Sulfiker, Seema Mishra, Ajay Ram A, Puneet Rathore, Bhanu Pratap Maurya, Nishkarsh Gupta, Sachidanand Jee Bharti, Rakesh Garg

Supportive Care in Cancer · 2026-12 · 34 (12)

DOI: 10.1007/s00520-026-11459-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 07.11.2026. Verfasst von Suhana Sulfiker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Onco-Anaesthesia & Palliative Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India. Hauptthemen laut MEDLINE: Dexamethasone, Nausea, Vomiting, Antiemetics. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Opioid-induced nausea and vomiting (OINV) is a common, distressing complication when starting opioids in cancer patients, yet evidence for prophylaxis is limited, and no randomised trial has evaluated dexamethasone in this setting. We assessed whether prophylactic dexamethasone reduces nausea and vomiting following initiation of oral morphine in opioid-naïve cancer patients. METHODS: In this open-label, randomised controlled trial at a tertiary cancer centre, opioid-naïve adults initiating oral morphine were randomised 1:1 to prophylactic oral dexamethasone or no prophylaxis. Rescue antiemetics were given in both arms. The primary outcome was nausea severity on an 11-point numerical rating scale (NRS) at Days 1, 3 and 5. Secondary outcomes were vomiting episodes and rescue antiemetic use. Analyses followed the intention-to-treat principle, with multivariable logistic regression adjusting for clinical covariates. RESULTS: Of 180 patients screened, 150 were randomised (dexamethasone n = 74; control n = 76). Mean nausea severity was lower with dexamethasone at all timepoints (Day 1: 1.36 vs 2.93; Day 5: 0.74 vs 1.53; both p ≤ 0.01), with a number needed to treat of 5 on Day 1 to prevent one episode of clinically meaningful nausea (NRS ≥ 4). The benefit persisted after adjustment (Day 1 aOR 0.38, 95% CI 0.19-0.75). Vomiting episodes were significantly reduced on Day 1. No serious adverse events occurred, and no patient discontinued treatment because of an adverse event. CONCLUSION: Prophylactic dexamethasone was associated with lower nausea severity during the critical early period of oral morphine initiation and was well tolerated. Dexamethasone is a widely available and inexpensive agent that warrants confirmation in larger multicentre trials. TRIAL REGISTRATION: CTRI/2026/02/104005, prospectively registered on 16 February 2026.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneNauseaVomitingAntiemeticsAnalgesics, OpioidMorphineNeoplasmsHumansFemaleMaleMiddle AgedAgedAdultAdministration, OralSeverity of Illness IndexLogistic Models

Stichwörter der Autor:innen

Antiemetic prophylaxisCancer painDexamethasoneMorphineOpioid-induced nausea and vomitingPalliative care

Substanzen

DexamethasoneAntiemeticsAnalgesics, OpioidMorphine

Autor:innen und Institutionen

  • Department of Onco-Anaesthesia & Palliative Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India.
  • Department of Onco-Anaesthesia & Palliative Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, 110029, India. seemamishra2003@gmail.com.

Zitieren

APA

Sulfiker, S., Mishra, S., A, A. R., Rathore, P., Maurya, B. P., Gupta, N., Bharti, S. J., & Garg, R. (2026). Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial). Supportive Care in Cancer, 34(12). https://doi.org/10.1007/s00520-026-11459-3

Vancouver

Sulfiker S, Mishra S, A AR, Rathore P, Maurya BP, Gupta N, et al. Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial). Supportive Care in Cancer. 2026;34(12). doi:10.1007/s00520-026-11459-3

BibTeX
@article{Sulfiker2026,
  author = {Sulfiker, Suhana and Mishra, Seema and A, Ajay Ram and Rathore, Puneet and Maurya, Bhanu Pratap and Gupta, Nishkarsh and Bharti, Sachidanand Jee and Garg, Rakesh},
  title = {Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial)},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {12},
  doi = {10.1007/s00520-026-11459-3}
}
Kostenlos starten →